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Abstract Genetic polymorphisms involved in angiogenesis, apoptosis and chemokine signalling are associated with varying ovarian
response and oocyte quality. The protein, histidine-rich glycoprotein (HRG), is involved in these processes, but its effect on ovarian
response in IVF has not been previously studied. A single nucleotide polymorphism (SNP) in the HRG gene (C633T) seems to affect
pregnancy results in IVF. Women with the C/C genotype had higher pregnancy rates, C/T had moderate rates and none of those in
the T/T group conceived. The aim of this study was to investigate if the HRG C633T SNP affects ovarian response. The HRG C633T
SNP genotype of 67 women with unexplained infertility undergoing IVF was analysed and related to medical data. The T/T genotype
obtained fewer oocytes, including mature oocytes, despite higher dosages of FSH administered. Additionally, the highest proportion
of women who had exclusively poor-quality embryos was in the T/T group. No differences in demographic factors known to affect
these parameters were found. The results suggest that the HRG C633T SNP inﬂuences ovarian response. Further studies of this SNP
may increase knowledge about the biological processes involved in oocyte development and, furthermore, improve predicted ovarian
response and fertilization.
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Introduction
The ultimate goal of IVF is to have a successful live birth of
a healthy child; however, several variables during treat-
ment indicate a higher or lower chance of pregnancy (van
Loendersloot et al., 2010). The sensitivity of the ovaries to
FSH given during ovarian stimulation is individual and is af-
fected by factors such as age, body mass index (BMI), smoking,
basal FSH levels, anti-Müllerian hormone (AMH) levels and
antral follicle count (AFC) (Broekmans et al., 2006; Holte et al.,
2011). The emerging best predictors of ovarian response are
AMH and AFC (La Marca and Sunkara, 2014; Nelson, 2013). The
sensitivity and speciﬁcity of all of the above mentioned factors
are low, however, with considerable inter-individual differ-
ences in response (Broekmans et al., 2006).
A patient’s response to IVF medications is also depen-
dent upon her genetic makeup, including different varia-
tions owing to single nucleotide polymorphisms (SNP). For
example, genetic variations of genes coding for LH (Alviggi
et al., 2009), the oestrogen receptor (Altmae et al., 2007)
and the FSH receptor (Perez Mayorga et al., 2000) have been
associated with FSH sensitivity and ovarian response in IVF
patients. Hence, it has been suggested that genetic screen-
ing may, in the future, help clinicians optimize treatment
strategies and improve predictions of ovarian response and
IVF outcome (Alviggi et al., 2012).
We have previously shown that a genetic variant of the
histidine-rich glycoprotein (HRG) gene seems to affect preg-
nancy success rate in IVF (Nordqvist et al., 2011). The SNP
at position 633 in the HRG gene consists of a cytosine (C633)
or thymine (633T). A cytosine (C) at this position will code
for a proline in the HRG protein at amino acid position 204
(sometimes denoted as position 186 if the signal protein is not
included). A thymine (T), however, will code for a serine
instead. The serine form allows for a glycosylation in the
protein. This SNP has also been assigned the National Center
for Biotechnology Information (NCBI) reference SNP identi-
ﬁcation tag rs9898. Women with unexplained infertility who
are homozygous for the HRG C633 SNP (C/C) (also denoted
previously as Pro/Pro) seem to have higher than expected
pregnancy rates, heterozygous women (C/T) (also denoted
as Pro/Ser) moderate rates and women homozygous for the
HRG 633T SNP (T/T) (also denoted as Ser/Ser) have lower than
expected pregnancy rates (Nordqvist et al., 2011). Addition-
ally, this SNP is associated with recurrent spontaneous
abortion, with the T/T group having an increased risk (Lindgren
et al., 2013).
Histidine-rich glycoprotein is a plasma glycoprotein in-
volved in biological systems, such as ﬁbrinolysis and coagu-
lation, the immunological response system, apoptosis and
angiogenesis (Poon et al., 2011). These systems are known
to be involved in oocyte development and pregnancy
(Haller-Kikkatalo et al., 2012; Van Blerkom et al., 1997).
Although its exact biomolecular function is unclear, HRG seems
to be an adaptor molecule owing to its unique molecular
structure, which allows it to interact with a multitude of dif-
ferent ligands. It has previously been reported to interact with
molecules such as heparin, ﬁbrinogen, plasmin and plasmino-
gen, thrombospondin, vascular endothelial growth factor
(VEGF) and various members of the ﬁbroblast growth factor
(FGF) family (Jones et al., 2005; Wake et al., 2009). Many of
these ligands are associated with infertility (Barroso et al.,
1999; Chaves et al., 2012; Ebisch et al., 2008; Richards, 2005).
Low pH (Borza, 2005) or interaction with Zn2+ affects ligand
binding through conformational changes in the HRG mol-
ecule (Jones et al., 2004). A recent study, using a new puri-
ﬁcation method, suggests that some previously reported
functions of HRG, such as removal of necrotic cells, may not
be through interactions between HRG and various ligands but,
instead, due to the presence, activity of co-puriﬁed mol-
ecules in the HRG-complex, or both (Patel et al., 2013). This
study by Patel et al. (2013) is also the ﬁrst to suggest a pos-
sible phosphorylation of HRG. Thus, HRG is an adapter mol-
ecule, bringing together different ligands, suggesting that it
regulates several important biological systems, many of
which are associated with infertility (Blank and Shoenfeld,
2008).
Since the HRG C633T SNP seems to affect pregnancy results
in IVF, it may be hypothesized that this SNP could affect
ovarian response. The aim of this study was to investigate if
the HRG C633T SNP is associated with ovarian response and
fertilization in IVF.
Material and methods
Women diagnosed with unexplained infertility were re-
cruited at an IVF Clinic (Fertilitetscentrum Stockholm)
between 1 March 2010 and 6 February 2012. This study was
part of a larger study in which 155 women with diverse
causes of infertility were included. Each woman contrib-
uted a blood sample only once. All women had previously
undergone assessment for cause of infertility. Women were
screened for anovulation, including polycystic ovarian syn-
drome (PCOS) according to Rotterdam criteria (Rotterdam
Eshre/Asrm-Sponsored Pcos Consensus Workshop Group, 2004),
thyroid dysfunction, tubal factors, male factors, endome-
triosis and uterus anomalies. Basal FSH levels or AMH levels
were tested on all women. Basal FSH levels below 13 IU/L or
AMH levels above 0.7 ng/ml were considered normal. Sperm
counts below the World Health Organization guideline levels
(Tocci and Lucchini, 2010) were classiﬁed as male infertil-
ity. When the above mentioned factors were absent, the
infertility was classiﬁed as unexplained. On the basis of the
strong association between the HRG C633T SNP and unex-
plained infertility, the analysis was continued focusing on this
sub-group of 67 women. Four women had previously given birth
to a child.
Treatment background
The HRG C633T SNP was successfully analysed in 67 women.
The mean treatment number was 1 ± 1 SD (minimum = 1,
maximum = 5). Starting dosages of FSH were determined
individually based on anticipated ovarian response and,
whenever possible, on previous treatment results. Ultra-
sound evaluation began on stimulation day 5–10 and
repeated if necessary. Dosages could be changed at the ul-
trasound depending on results. A gonadotropin releasing
hormone (GnRH) agonist protocol was used for 12 women com-
posed of buserelin (Suprecur; Sanoﬁ-Aventis, Stockholm,
Sweden) (n = 3); nafarelin (Synarela; Pﬁzer, Sollentuna,
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Sweden) (n = 9) and a GnRH antagonist protocol was used for
55 women composed of ganirelix (Orgalutran; MSD, Sollentuna,
Sweden) from stimulation day 5 or 6 (Table 1). Fifty-ﬁve
women used recombinant FSH follitropin alpha (Gonal F; Merck
Serono, Solna, Sweden) (n = 25) and follitropin beta (Puregon,
MSD) (n = 30); and 12 used human menopausal gonadotro-
pins (hMG) menotropin (Menopur, Ferring Malmö, Sweden)
(n = 11) and urofollitropin (Fostimon; NordicInfu Care, Nacka
Strand, Sweden) (n = 1). The patients were monitored by ul-
trasound, and ovulation was induced when at least three fol-
licles were 15 mm or larger in an antagonist cycle or 17 mm
or larger in an agonist cycle. Ovulation was induced by a sub-
cutaneous injection of HCG alfa 6500 IU (Ovitrell, Merck
Serono, Solna, Sweden) (n = 64) or 10 000 IU (Pregnyl; MSD,
Sollentuna, Sweden) (n = 3) given 37 h before oocyte re-
trieval. For fertilization of the oocytes, standard IVF was used
for 56 patients, intracytoplasmic sperm injection treatment
(ICSI) for seven patients and a combination of both methods
for four patients. In women with a low fertilization rate in a
previous treatment cycle, ICSI or a combination of methods,
was used (Table 1).
Collection of blood samples
A venous blood sample was collected in ethylene-diamine-
tetraacetic acid tubes (Vacuette, GBO, Austria) on the day
of oocyte retrieval. The blood samples were centrifuged at
1500 g for 10 min. Buffy coat was extracted, transferred to
new tubes (2 ml tubes, Sarstedt, Germany) and immedi-
ately put into a temporary freezer (−20°C). The samples were
transferred weekly to a −70°C freezer.
Embryos were assessed according to standard clinical
morphological scoring protocol (Alpha-Scientists-In-
Reproductive-Medicine & Eshre-Special-Interest-Group-
Of-Embryology, 2011). Embryo transfer was not carried out
if embryos showed developmental delays or gross abnormali-
ties, such as excessive fragmentation, multinucleated blas-
tomeres or micronuclei.
Preparation of DNA and single nucleotide
polymorphism analysis
Genomic DNA was extracted from buffy coat samples using
QIAamp DNA Blood Maxi kits (Qiagen, Venlo, Netherlands). In
67 out of the 73 samples, DNA was successfully extracted from
women with unexplained infertility. The samples were
genotyped for the HRG C633T SNP in HRG exon 5 (rs9898) using
the TaqMan SNP Genotyping Assay (Applied Biosystems, Foster
City, CA, USA). Brieﬂy, polymerase chain reactions were
carried out in a 96-well plate in a total volume of 25 µl for
each reaction. Each reaction consisted of TaqMan Universal
PCR Master Mix (PCR buffer, ROX passive reference dye, dNTPs
and AmpliTaq Gold polymerase), SNP Genotyping Assay
(sequence-speciﬁc forward and reverse primers to amplify the
polymorphic sequence of interest (i.e. HRG exon 5, TaqMan
MGB probes labelled with VIC dye to detect allele 1 se-
quence and with FAM to detect allele 2 sequence) and 10 ng
of genomic DNA. Cycling conditions were initiated for 10 min
at 95°C followed by 40 cycles of 15 s at 92°C and 1 min at
60°C. Real-time ﬂuorescence detection was carried out. Se-
quence Detection System software (Applied Biosystems) was
used to plot ﬂuorescence (Rn) values based on the signals from
each well. The plotted ﬂuorescence signals indicated which
alleles were present in each sample.
The women were grouped according to the HRG SNP results:
homozygous HRG C633 (C/C); heterozygous HRG C633T (C/
T); or homozygous HRG 633T (T/T). Data concerning medical
history, treatment and results were obtained from patients’
medical records.
Statistical analysis
Differences in proportions of women between the different
HRG C663T SNP groups for nominal data were analysed
using a chi-squared test. When the chi-squared test was not
applicable, a Fisher’s exact test was used. Mann–Whitney U
test was used to evaluate comparison between medians for
Table 1 Treatment parameters stratiﬁed by HRG C633T single nucleotide polymorphism.a
HRG C633T SNP
C/C C/T T/T
n (%) 39 (58.2) 23 (34.3) 5 (7.5)
Treatment numberb 1.0 (1.0–2.0) 1.0 (1.0–2.0) 2.0 (1.0–4.5)
IVF n (%)c 33 (84.6) 20 (87.0) 3 (60.0)
ICSI n (%)c 3 (7.7) 2 (8.7) 2 (40.0)
Combined IVF/ICSI n (%)c 3 (7.7) 1 (4.3) 0
Agonist n (%)c 6 (15.4) 4 (17.4) 2 (40.0)
Antagonist n (%)c 33 (84.6) 19 (82.6) 3 (60.0)
rFSH n (%)c 33 (84.6) 19 (82.6) 3 (60.0)
hMG n (%)c 6 (15.4) 4 (17.4) 2 (40.0)
C/C, homozygous for the HRG C633 SNP; C/T, heterozygous for the HRG C633T SNP; hMG, human
menopausal gonadotrophin; HRG, histidine-rich glycoprotein; rFSH, recombinant FSH; SNP, single
nucleotide polymorphism; T/T, homozygous for the HRG 633T SNP.
aData are median (interquartile range) unless otherwise stated.
bNon-signiﬁcance using the Mann–Whitney U test; treatment number is the number of the current
treatment.
cNon-signiﬁcance using a Chi-square test or a Fischer’s exact test when applicable.
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ordinal or continuous data for the different genotypes. Each
group was compared with the other groups individually and
with the other two groups combined. All statistical tests
performed were two-sided with P ≤ 0.05 considered statis-
tically signiﬁcant. IBM SPSS version 20 (IBM Corporation,
Armonk, NY) was used for all analyses.
Ethical approval
The study was approved by the Regional Ethics Committee of
the Medical Faculty of Uppsala University Hospital (Diary
numbers: 2007/3-31/3, 2007/1559-32, approval 7 March, 2007;
2010/0180-32, amendment approval 12 February 12, 2010).
Written and verbal information was given by a healthcare
professional. Each participating patient gave her written
informed consent. No reimbursement was given to partici-
pating patients. Women not able to understand Swedish or
English were excluded.
Results
Demographics
In a European population, the HRG C633T has a reported
frequency of 47.2% for C/C, 41.7% heterozygous (C/T) and
11.1% T/T (http://www.ensembl.org/Homo_sapiens/
Variation/Explore?r=3:186672338-186673338;v=rs9898;vdb
=variation;vf=9018). In this study, the distribution of this geno-
type was similar (C/C 58.2%, C/T 34.3%, T/T 7.4%). Demo-
graphics for the different HRG C633T SNPs are shown in
Table 2. No differences were found between groups in age,
BMI, length of infertility or menstrual cycle length. Basal FSH,
AMH and AFC were comparable. A lower proportion of women
in the T/T group tended to have had a previous pregnancy
or child compared with those in the C/C or the C/T group.
Treatment parameters
No differences were found between the HRG SNP groups in
treatment number, method used (IVF, ICSI or combined), treat-
ment protocol type (agonist or antagonist), type of FSH (rFSH
or hMG) or oocyte retrieval day (Tables 1 and 3). Women in
the T/T group were given a signiﬁcantly higher total amount
of FSH compared with the others (P < 0.05) (Table 3).
Treatment results
Although there was no difference in the mean OPU day, the
median number of oocytes retrieved was higher for the C/C
group and the C/T group compared with the T/T group. The
T/T group also obtained fewer mature oocytes, although the
number of immature oocytes was the same in all groups. Ad-
ditionally, the number of fertilized oocytes was lowest in the
T/T group (Table 3). There was a non-signiﬁcant trend towards
a higher proportion of women who had exclusively poor quality
embryos unﬁt for transfer in the T/T group. All poor quality
embryos were unﬁt for transfer during early development, no
later than day 3. The T/T group had the highest proportion
(40%) compared with the C/T (17.4 %) or the C/C group (5.1%)
(Table 3).
Table 2 Demographic and anthropometric variables for women stratiﬁed by HRG C633T
single nucleotide polymorphism.a
HRG C633T SNP
C/C C/T T/T
n (%) 39 (58.2) 23 (34.3) 5 (7.5)
Age (years)b 35.0 (32.0–37.0) 34.0 (30.0–38.0) 33.0 (32.0–36.5)
BMI (kg/m2)b 22.6 (21.0–24.0) 23.0 (20.0–24.0) 21.6 (21.0–27.3)
Infertility duration (years)b 3.0 (2.0–3.3) 2.3 (2.0–3.1) 2.5 (1.2–6.8)
Current smokers n (%)c 4/38 (10.5) 1 (4.3) 1 (20.0)
Menstrual cycle length (days)b 28.0 (26.0–30.0) 28.0 (26.0–29.0) 28.0 (27.0–30.0)
Basal FSH (IU/L)b 6.3 (4.8–7.1) 6.1 (5.4–8.8) 6.6d
AMH (ng/ml)b 1.8 (9.5–16.0) 2.0 (1.4–3.0) 1.6d
AFCa 13.5 (9.5–16.0) 14.0 (9.5–16.0) 16.0 (11.0–19.0)
Previous pregnancy n (%)c 13 (33.3) 12 (52.2) 1 (20.0)
Previous miscarriage n (%)c 7 (17.9) 7 (30.4) 1 (20.0)
Previous child n (%)c 4 (10.3) 0 (0) 0 (0)
AFC, antral follicle count; AMH, anti-Müllerian hormone; BMI, body mass index; C/C = homo-
zygous for the HRG C633 SNP; C/T, heterozygous for the HRG C633T SNP; HRG, histidine-rich
glycoprotein; SNP, single nucleotide polymorphism; T/T, homozygous for the HRG 633T SNP.
aData are median (interquartile range) unless otherwise noted.
bNon-signiﬁcance using the Mann–Whitney U test.
cNon-signiﬁcance using a chi-squared test or a Fisher’s exact test when applicable. dInterquartile
range not calculated. Women were screened with either FSH or AMH. Both basal FSH and AMH
values missing for one woman. The values for the remaining four women are as follows: basal
FSH = 5.5 IU/L; basal FSH = 7.6 IU/L; AMH = 1.6 IU/ml and AMH = 1.7 IU/ml.
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Discussion
Ovarian response during IVF stimulation is known to be as-
sociated with pregnancy rate and the chance of a live birth
(van Loendersloot et al., 2010). Current research has focused
on demographic differences between patient groups and on
possible mechanisms regulating ovarian response. A number
of different factors such as age, BMI, smoking, basal FSH levels,
AMH levels and AFC are known to affect ovarian response and
are well described, but the sensitivity and speciﬁcity are not
precise (Broekmans et al., 2006). The HRG C633T genotype
seems to regulate the number of mature oocytes possible to
retrieve and, thereby, the number of oocytes fertilized,
despite lack of differences in demographic factors known to
affect these results. The T/T genotype produced a lower
number of oocytes including mature oocytes, despite the
higher dosages of FSH administered. The number of imma-
ture oocytes did not differ between the groups. Addition-
ally, women in the T/T group tended to be at risk for no
transfer owing to developing exclusively poor-quality embryos
unﬁt for transfer. Genotype was determined after embryo
transfer and, thus blinded for personnel, eliminating pos-
sible confounders.
In the general population, individuals with the T/T geno-
type have higher plasma levels of HRG (Hennis et al., 1995a)
than those with the C/C genotype. It has recently been dis-
covered that HRG may be phosphorylated (Patel et al., 2013).
Differences in phosphorylation have been associated with age-
related variations of levels of plasma proteins (Drasin and
Sahud, 1996; Ignjatovic et al., 2011). Since the HRG C633T
SNP also affects HRG plasma level, it would be interesting to
study further if this SNP allows for differences in phosphory-
lation, which might affect different biological mechanisms.
These variations in HRG protein levels as such might affect
ovarian response and oocyte quality. Ovarian response or
oocyte quality, however, might be affected instead through
differences in interactions with various ligands owing to
changes in the molecular structure of the HRG protein. These
differences in interactions could affect biological functions,
such as angiogenesis regulation.
The predominant form of the human HRG protein encodes
a proline at position 204 (or position 186 when signal peptide
is excluded), corresponding to the SNP HRG C633. As far
as is known, this variant is unique for humans because no other
species, including chimpanzees, have a proline at this
position. (http://www.ncbi.nlm.nih.gov/homologene?cmd
=Retrieve&dopt=MultipleAlignment&list_uids=133557). The
HRG 633T SNP codes instead for a serine residue at this po-
sition, which allows for the glycosylation site Asn-X-Ser (Hennis
et al., 1995b; Spiro, 2002). The presence of a glycosylation
at this position has recently been conﬁrmed in the crystal
structure of rabbit HRG (Asn184) (Kassaar et al., 2014). The
crystal structure of human HRG with the predominant proline
at this critical position has not yet been determined, but
the absence of glycosylation in this form is well docu-
mented (Hennis et al., 1995b; Koide et al., 1986; Patel et al.,
2013). It is noteworthy that the glycosylation site lies in
close vicinity to a disulphide bond between the N2 domain
of the HRG protein and the proteolytic HRR/PRR fragment (Cys
185–Cys 407) that is of great importance for HRG regulated
angiogenesis (Dixelius et al., 2006; Hennis et al., 1995b;
Kassaar et al., 2014; Lee et al., 2006). It is tempting to specu-
late that the polymorphism and the absence or presence of
glycosylation at Asn184 has an inﬂuence on the stability of
the disulphide bond at Cys 185, and thereby alters regula-
tion and the potential release of the proteolytic HRR/PRR
fragment and, consequently, interacts with regulation of
angiogenesis.
The altered angiogenesis might subsequently modulate
the effect on ovarian response, oocyte quality, or both. These
interactions may be affected as early as the fetus stage
because angiogenesis is an important process in the devel-
opment of a properly functioning ovary (McFee and Cupp,
2013). Angiogenesis may also affect the depletion of ovarian
Table 3 IVF treatment parameters stratiﬁed by HRG C633T single nucleotide polymorphism.a
HRG C633T SNP
C/C C/T T/T P-value
n (%) 39 (58.2) 23 (34.3) 5 (7.5)
Total FSH (IU/L) 1875 (1350–2250) 1650 (1250–3000) 3150 (1363–6038) <0.05b
Oocyte retrieval day 13 (12–14) 13 (12–14) 16 (11–17) NS
Oocytes harvested 8 (6.0–13.0) 8 (6.0–11.0) 5 (3.0–6.5) <0.05c
MII oocytes harvested 8 (5.0–12.0) 7 (5.0–9.0) 4 (2.0–5.5) <0.05c
MI oocytes harvested 0 (0–1.0) 0 (0–1.0) 0 (0–1.0) NS
GV oocytes harvested 0 (0–0) 0 (0–1.0) 0 (0–1.5) NS
Fertilized oocytes 6 (3.0–9.0) 5 (3.0–7.0) 2 (2.0–4.0) <0.05d
No embryos transferred n (%) 2 (5.1) 4 (17.4) 2 (40.0) NS
C/C, homozygous for the HRG C633 SNP; C/T, heterozygous for the HRG C633T SNP; GV, immature oocyte, germinal vesicle; HRG, histidine-
rich glycoprotein; MI, immature oocyte, metaphase I; MII, mature oocyte; No embryos transferred, proportion of women who had exclu-
sively poor quality embryos unﬁt for transfer; NS, non-signiﬁcance; SNP, single nucleotide polymorphism; T/T, homozygous for the HRG 633T
SNP.
aData are median (interquartile range) unless otherwise stated. Mann–Whitney U test was used to evaluate comparison between medians.
For ‘no embryo transfer’, Fischer’s exact test was used to evaluate comparisons between proportions.
bComparing C/C with the other two groups combined.
cComparing C/C to T/T, C/T to T/T and T/T with the other two groups combined.
dComparing C/C with T/T and comparing T/T with other two groups combined.
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reserve. Altered vascular patterns have been found in the
ovaries of aging women (Delgado-Rosas et al., 2009). As AMH,
AFC and basal FSH were similar for the HRG C663T groups,
it is more likely that folliculogenesis is affected rather than
ovarian reserve. Adequate blood vessel development is es-
sential to folliculogenesis because it also provides sufﬁcient
nutrients, oxygen and hormones to developing follicles and
facilitates removal of metabolites and carbon dioxide.
Histidine-rich glycoprotein interacts with other angio-
genic factors, such as VEGF (Olsson et al., 2004) and FGF
(Brown and Parish, 1994; Freeman and Parish, 1997; Juarez
et al., 2002), but no studies to date have shown how HRG
affects angiogenesis in the follicle. Different isoforms of VEGF
as well as various members of the FGF family, however, have
been shown to be involved in the regulation of folliculogenesis
and oocyte development (Chaves et al., 2012; McFee et al.,
2009).
The oocyte and surrounding cumulus cells communicate
via paracrine and gap-junctional signaling (Sutton et al., 2003).
Oocytes fail to develop if this communication is interrupted
(Ackert et al., 2001; Matzuk et al., 2002). Recent studies have
examined differences in gene expression in cumulus cells to
facilitate prediction of oocyte quality (Fragouli et al., 2012).
Van Montfoort et al. (2008) carried out a genome-wide study
of genes expressed in cumulus cells and correlated gene ex-
pression with embryo viability. Differences between early
cleavage embryos and non-early cleavage embryos were found
in genes involved in angiogenesis, apoptosis, various growth
factors signalling, including FGF signalling, general vesicle
transport and chemokines and cytokine signaling. Histidine-
rich glycoprotein is involved in many of these processes
(Wakabayashi and Koide, 2011).
The communication between granulosa cells, cumulus cells
and the oocyte is facilitated by follicular ﬂuid microvesicles
containing biologically active material. da Silveira et al. (2012)
studied the contents of these microvesicles in mares and found
that they contained an HRG-like protein (da Silveira et al.,
2012). Histidine-rich glycoprotein has previously been iden-
tiﬁed in human follicular ﬂuid (Ambekar et al., 2013; Nordqvist
et al., 2010). Additionally, high levels of VEGF in follicular
ﬂuid have been associated with low fertilization rates
(Malamitsi-Puchner et al., 2001) and poor quality embryos
(Barroso et al., 1999). The proteomic proﬁles of human fol-
licular ﬂuid from follicles containing oocytes, which became
fertilized, reveal an up-regulation of the heparan sulfate
proteoglycan perlecan as compared with the levels in the fol-
licles containing oocytes, which did not become fertilized
(Bayasula et al., 2013). The interaction between HRG and
heparan sulfate is known to be of relevance in angiogenesis
(Freeman and Parish, 1997).
Strengths and limitations
As far as is known, this is the ﬁrst study investigating the effect
of HRG on ovarian response and oocyte fertilization. This study
is population based, and each woman attending the clinic
during the speciﬁc study period was invited to participate.
The population is well deﬁned in terms of background factors,
treatment protocol and results. Larger studies are needed
to verify the results. Although no clear explanation of the
underlying biological mechanisms is provided, the ﬁndings
generate hypotheses for future studies. This study exam-
ines only the HRG C633T SNP and does not include further
analysis of the association between this SNP and other SNP
known to affect ovarian response and other IVF outcome
parameters.
Clinical signiﬁcance and future studies
The biological mechanism behind the role of the HRG C633T
SNP in fertility may increase our understanding of the
processes involved in ovarian response and oocyte develop-
ment. Enhanced prediction of ovarian response, oocyte yield,
fertilization rates and embryo quality will reduce risks for
patients due to inappropriate FSH dosages, enhance coun-
selling of patients and/or improve results in IVF. Further in-
vitro studies may help clarify the biological mechanisms behind
the effect of the HRG C633T SNP on ovarian response, oocyte
quality and embryo quality. The prevalence and effect of this
polymorphism in women who have a high or low ovarian re-
sponse after stimulation for IVF would give further informa-
tion on the effect of the genotype. No studies have
investigated the association between this polymorphism and
male fertility or sperm quality. As the HRG C633T SNP has been
related to recurrent pregnancy loss (Lindgren et al., 2013),
it would also be interesting to determine the effect of the
genotype on time to conception or to live birth in normally
fertile women, women with PCOS and low-responders.
In conclusion, the genotype seems to regulate the number
of mature oocytes possible to retrieve and, thus, the number
of oocytes fertilized. Those with the least number of oocytes
received the highest amounts of FSH. Therefore, adequate
regulation of HRG seems to be important for ovarian
response.
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